Pemetinib research and development history, price information and formal purchase channels

Pemigatinib (Pemigatinib), widely known by the trade name Pemazyre, is a new small molecule kinase inhibitor developed and commercialized by Incyte Biopharmaceutical Company in collaboration with Innovent Biologics. Its research and development background is deeply rooted in a deep concern for the treatment needs of cholangiocarcinoma (CCA). Cholangiocarcinoma, a malignant tumor originating from bile duct epithelial cells, has continued to increase in incidence in recent years, but treatment options are relatively limited. Especially for patients with advanced or metastatic cholangiocarcinoma, treatment options are even more scarce.

The development of pemetinib focuses on the potent and selective inhibition of the fibroblast growth factor receptor (FGFR) signaling pathway. FGFR gene mutations are found in a variety of tumors, and they promote the development of malignant tumors by promoting the proliferation, survival, migration, and angiogenesis of tumor cells. Pemetinib can specifically inhibit FGFR1, FGFR2 and FGFR3, thereby effectively curbing tumor growth.

During the development process, pemetinib underwent rigorous clinical trial verification. In particular, the Phase II clinical trial FIGHT-202 evaluated the efficacy and safety of pemetinib in patients with metastatic/advanced or unresectable cholangiocarcinoma who have failed prior treatment. The trial results showed that pemetinib performed well in terms of disease control rate and response rate, bringing new treatment hope to patients with cholangiocarcinoma.

In terms of price, as an innovative drug, the price of pemetinib is relatively high. The market price of original drugs can reach tens of thousands of yuan per box. However, there are also more affordable versions overseas, such as generic drugs produced by Lucius Pharmaceuticals in Laos, which sell for about 800 to 900 yuan per box.

In order to ensure that patients can purchase regular and safe pemetinib, the following are some recommended purchasing channels:

1. Purchase through formal channels: For original drugs, it is recommended that patients purchase them through hospital pharmacies or formal online pharmacies to ensure the quality and safety of the drugs.

2. Consultation from overseas medical institutions: For generic drugs, patients can consult professional overseas medical institutions. But be sure to choose a reputable and qualified agency to ensure the reliability of the source of the medicine.

3. Understand the indications, usage and dosage: Before purchasing, patients should consult their doctor to understand whether their condition is suitable for the use of pemetinib, and to learn more about the correct usage and dosage.

In summary, pemetinib, as an innovative drug, provides a new treatment option for patients with cholangiocarcinoma. However, patients should be sure to choose formal channels when purchasing and fully understand the indications, usage and dosage of the medicine to ensure the effectiveness and economy of the treatment. There are currently different versions of pemetinib on the market, and patients can make a choice based on their own circumstances.